Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2002 Dec;120(6):897–906. doi: 10.1085/jgp.20028608

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2002, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 6. — PKC inhibitors prevent decrease of benzamil-sensitive Isc by UTP. (A) Representative trace showing the benzamil-sensitive current in the absence or presence UTP (5 μM), and after pretreatment with both Gö6983 (10 μM) and UTP, (n = 8, 14, and 9, respectively, N = 3). (B) Bar graph illustrating the benzamil-sensitive current after benzamil only (5 μM, n = 8), after UTP (5 μM, n = 14), after PMA (0.5 μM, n = 4), after UTP in the presence of Gö6983 (10 μM, n = 9), after UTP in the presence of rottlerin (2.5 μM, n = 5), after UTP in the presence of Gö6976 (100 nM, n = 6 and 10 μM, n = 4, respectively), or after UTP in the presence of the cell permeable, myristoylated PKC inhibitor 20–28 (10 μM, n = 4). Asterisk indicates significant differences compared with the benzamil-sensitive current after UTP. The benzamil-sensitive currents following pretreatment with rottlerin and Gö6983 (a nonselective PKC inhibitor) were not significantly different from benzamil treatment alone.